— Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim readout expected in the second half of 2025 — U.S. Food and ...

By Hugo Francisco de Souza Emerging research suggests reversible RNA editing mechanisms may influence heart disease biology while opening new avenues for biomarkers and next-generation cardiovascular ...

CAMBRIDGE, Mass., March 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...

Korro Bio, Inc. announced that its investigational drug KRRO-110 has received orphan drug designation from the FDA for treating Alpha-1 Antitrypsin Deficiency (AATD). This designation highlights the ...

— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD) on track for the second half of 2025 — Streamlining operations and focusing on delivering ...

Ascidian Therapeutics (“Ascidian”), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of the ...

Genetic editing holds promise to treat incurable diseases, but the most popular method - CRISPR - sometimes does more harm than good. A new study from University of California San Diego and Yale ...

Korro Bio Inc.’s latest update on RNA editing prospect KRRO-110 may mean one less competitor in alpha-1 antitrypsin deficiency (AATD), and shares of the firm (NASDAQ:KRRO) closed Nov. 13 at $6.50, ...

Genetic editing holds promise to treat incurable diseases, but the most popular method — CRISPR — sometimes does more harm than good. A new study from University of California San Diego and Yale ...

DNA is the backbone of the genetic code so, logically, decoding and understanding the genetic sequence along with epigenetic modifications came first. Yet, RNA and the emerging field of ...